Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

Summary

Angiogenesis, the development of new blood vessels, plays an important role in the disease development and tumor growth in many solid organ malignancies. Bevacizumab was the first anti-angiogenic drug to be approved in solid tumors and has shown advantageous activity with multiple tumor types. However, the responses from Bevacizumab are often transient due to the tumor's manipulative abilities to circumvent the usual pathways to find salvage pathways instead. Nintedanib has demonstrated anti-tumor activity in non-squamous non-small cell lung cancer, colorectal cancer, ovarian cancer, and renal cell cancer. The combination of Bevacizumab and Nintedanib are being proposed to target the tumor's manipulation processes to generate alternate pathways for angiogenesis thus creating a potential benefit to delay tumor growth.

Timeline

Start

2016-06-09

Primary completion

2018-04-14

Completion

2018-06-14

Publications

• Paluri R, Madan A, Li P, Jones B, Saleh M, Jerome M, Miley D, Keef J, Robert F. Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2019 Mar;83(3):551-559. doi: 10.1007/s00280-018-3761-y. Epub 2019 Jan 2.

Drugs

Indications